A GO analysis reveals that not only VGluT1 is present, but a more general synaptic gene alteration is present specifically at Braak stage 3 and 4, and a significant reduction in gene modulation follows at Braak stage 6 in the PFC of AD patients [146]. Here, SLC17A7 is linked to Alzheimer disease.